Table 7.

Test Characteristics of Undetectable Concentrations of hsTnT at ED Arrival for MACE Among 3,439 Patients With Serial Troponins Performed

hsTnT Cutoff (ng/L)	Patients Ruled Out	Outcome	Events Below Cutoff	Sensitivity (95% CI)	NPV (95% CI)	LR– (95% CI)
<3	331 (9.6%;	7‐day MACE	1	99.8	99.7	0.019
	95% CI = 8.7%–10.7%)			(98.8,100)	(93.3–100)	(0.003–0.138)
		30‐day MACE	2	99.6	99.4	0.035
				(98.6–100)	(97.8,100)	(0.009–0.140)
		90‐day MACE	2	99.6	99.4	0.032
				(98.6–100)	(97.8,100)	(0.008–0.129)
<5	800 (23.33%;	7‐day MACE	12	97.4	98.5	0.098
	95% CI = 21.9%–24.7%)			(95.5–98.7)	(99.1–99.7)	(0.056–0.171)
		30‐day MACE	18	96.5	97.8	0.133
				(94.5–97.9)	(96.5–98.6)	(0.084–0.209)
		90‐day MACE	19	96.5	97.6	0.129
				(94.6–97.9)	(96.3–98.6)	(0.082–0.201)
<6	1,026 (29.8%;	7‐day MACE	16	96.6	98.4	0.102
	95% CI = 28.3%–31.4%)			(94.5–98.0)	(97.5–99.1)	(0.063–0.165)
		30‐day MACE	25	95.1	97.6	0.144
				(92.8–96.9)	(96.4–98.4)	(0.098–0.212)
		90‐day MACE	26	95.3	97.5	0.138
				(93.1–96.9)	(96.3–98.3)	(0.094–0.201)

hsTnT = high‐sensitivity cardiac troponin T; LR– = negative likelihood ratio; MACE = major adverse cardiac events; NPV = negative predictive value.